"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 5 | 6 |
| 1999 | 0 | 3 | 3 |
| 2000 | 3 | 0 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 4 | 2 | 6 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 4 | 6 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 6 | 7 |
| 2011 | 1 | 5 | 6 |
| 2012 | 1 | 4 | 5 |
| 2013 | 4 | 3 | 7 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 6 | 8 |
| 2016 | 1 | 5 | 6 |
| 2017 | 6 | 6 | 12 |
| 2018 | 6 | 3 | 9 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 2 | 4 | 6 |
| 2024 | 6 | 4 | 10 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Unique methotrexate polyglutamates distributions in peripheral blood mononuclear cells of rheumatoid arthritis patients: Development and validation of a UPLC-MS/MS method. J Pharm Biomed Anal. 2025 Sep 01; 262:116882.
-
High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Glob Oncol. 2025 Mar; 11:e2400591.
-
Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Glob Oncol. 2025 Mar; 11:e2400450.
-
Infantile myofibromatosis: Small bumps pose big problems. J Neonatal Perinatal Med. 2025 Mar; 18(2):179-183.
-
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 Mar 10; 43(8):912-918.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
-
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study. J Rheumatol. 2024 Nov 01; 51(11):1125-1134.
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
-
Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus. Transplant Proc. 2024 Sep; 56(7):1671-1677.
-
Methotrexate: Borrowed Hope for Persons With Knee Osteoarthritis? Ann Intern Med. 2024 Sep; 177(9):1271-1272.